SHANGHAI, Oct. 17 /PRNewswire-Asia/ — At the end of 2009, the
vaccine industry raised so much concern worldwide that the
headlines of the business media were occupied by various kinds of
news about vaccine enterprises. For example, Sinovac Biotech Co.,
Ltd. successfully landed on the Nasdaq, then Simcere, a
pharmaceutical company based in Jiangsu Province, listed on the
NYSE, announced a 50.8% stake in Ealong Biotech and took control of
the latter, and finally Novartis, the world-famous pharmaceutical
company headquartered in Switzerland, acquired an 85.0% equity in
Tianyuan Bio-Pharmaceutical, a vaccine producer, for RMB850M. These
deals indicate that the investors and foreign pharmaceutical giants
have not slowed down their pace to enter China’s vaccine market,
even in the face of this economic recession.
Hosted by Global Leaders Institute, world vaccine industry
leaders convened at VacChina 2010 on Sept 15 and 16 in Shanghai.
The two-day executive summit featured over 30 speakers and
attendances from top executives including Junfang Gao, GM of
Changchun Changsheng Life Science and An Kang, Chairman of the
Board from Hualan Bio to share views on the latest China vaccine
industry regulatory environment, research capabilities, market
trends, and status of technology applications etc. Well attended by
over 200 attendees from vaccine producers home and abroad including
6 main institutes of biological products in China and top China
vaccine manufacturers like Zhejiang Tianyuan, Chengda Bio, Shanghai
United Cell, Wison Bio, Walvax, Tasly and Innovax gathered under
the same roof to look for partnering opportunities, VacChina 2010
was undoubtedly the most high end vaccine meeting held in China
this year. Besides, thanks to over 20 corporate sponsors showcasing
their state of the art vaccine R&D technologies at the event,
VacChina 2010 is also a premier platform for various technology
providers presenting their latest advancements in vaccine
bioreactor, cell
‘/>”/>
